3648 results for «383»

Filter By

3648 results

Focus on heart failure: from acute to chronic

21 May 2026 – From EuroPCR 2026

This comprehensive session delves into the spectrum of heart failure management, from acute presentations to chronic conditions. Key topics include the cardio-hepatic syndrome and right ventricular dysfunction in HFmrEF, prognostic implications of heart failure etiologies, and innovative approaches such as AI-assisted echocardiography for early detection of...

Strategies to enhance bifurcation PCI outcomes

21 May 2026 – From EuroPCR 2026

This session addresses strategies to optimize outcomes in coronary bifurcation PCI. It evaluates the impact of cutting and scoring balloons versus non-compliant balloons on stent expansion, predictors of target vessel revascularization using the POKI technique, and compares stent and non-stent approaches in side branch myocardial infarction...

Aortic stenosis: from diagnostic to treatment

21 May 2026 – From EuroPCR 2026

This session provides an in-depth review of contemporary management of aortic stenosis, covering diagnostic advancements, temporal trends, and treatment outcomes. It includes insights from the LAPLACE-TAVI registry focusing on low-risk patients, discusses the growing feasibility of day-case TAVI procedures, compares transcatheter and surgical valve replacements in...

Left main PCI, what is known and what is new

21 May 2026 – From EuroPCR 2026

This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Alessandro Sticchi

Author

Alessandro Sticchi
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)

08 Apr 2024

Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.

Ali Nazmi Calik

Author

Ali Nazmi Calik
Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques

The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone versus placebo in patients with myocardial infarction

18 Nov 2024

Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
CLEAR SYNERGY

NOTION-3 - Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation

01 Sep 2024

Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.

Author

Chiara De Biase
Jacob Lønborg

Author

Jacob Lønborg
Ali Nazmi Calik

Author

Ali Nazmi Calik
NOTION 3
Didn’t find what you were looking for?